Upshot of Chemotherapy On Gross Survival Appears Amplified Based On Tumor Size


Advertisement
by Nancy Needhima on  May 22, 2012 at 3:03 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
Possibility of a positive correlation amid tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer as pointed by latest research released in June's Journal of Thoracic Oncology. The study, published in the June 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, analyzed the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum based chemotherapy in patients with node negative non-small cell lung cancer.
Upshot of Chemotherapy On Gross Survival Appears Amplified Based On Tumor Size

The purpose of the retrospective study was to apply the most current, 7th edition, TNM staging system, to a retrospective cohort of surgically resected, node negative, non-small cell lung cancer patients who were treated with adjuvant platinum based chemotherapy. Previous clinical trials confirmed a survival benefit for adjuvant platinum based chemotherapy for patients with stage II-IIIa non-small cell lung cancer. In addition, the authors explored the interaction between tumor size and KRAS mutations in predicting a benefit from the chemotherapy.

After analyzing data from 461 patients that were part of two previous adjuvant trials, JBR.10 and CALBG 9633, the authors found a positive correlation between the size of the tumor and efficacy of chemotherapy with respect to disease free survival. There was no clear demarcation of what T size threshold correlated with benefit of chemotherapy. KRAS mutation was detected in 27 percent of the specimens, correlated with a worse prognosis but not with the size of the tumor.

"Thus, our study reinforces the pressing need for improved understanding of the impact of the new T-size descriptors on adjuvant chemotherapy effect," the authors say. "This is particularly valid when we consider that up to 77 percent of surveyed lung cancer physicians would alter patient management in response to a change in stage designation."

Source-Eurekalert
Do you like this Report?
0

 Email Email  RSS Feeds RSS Feeds  Print this page Print  Save this page Save  Link Link  Syndicate Syndicate  Comments Comments 
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Related Links

Cancer Related News

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Chemotherapy
Complete Medindia Resources
News Categories:  
Mental Health Center